Vivus reviews its options post-Viagra
This article was originally published in Clinica
Executive Summary
Vivus has retained an investment bank to search for a possible buyer for the company as it has seen the short term prospects for its erectile dysfunction therapies suffer, from the success of Pfizer's pharmaceutical alternative, Viagra.